{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:55:52Z","timestamp":1781528152151,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107147","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T16:02:15Z","timestamp":1773676935000},"page":"107147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4864-1429","authenticated-orcid":false,"given":"Liza M.Y.","family":"Gelissen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M.M.","family":"Strijbis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bob W.","family":"van Oosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes I.","family":"Veldkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theo","family":"Rispens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zo\u00e9 L.E.","family":"van Kempen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107147_bib0001","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107147_bib0002","article-title":"Assessment Report: tyruko","year":"2024","journal-title":"Int. Non-Propr. name: Natalizumab"},{"key":"10.1016\/j.msard.2026.107147_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurot.2024.e00351","article-title":"Extended interval dosing of natalizumab: more evidence in support","volume":"21","author":"Toljan","year":"2024","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.msard.2026.107147_bib0004","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJMoa1107829","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy","volume":"366","author":"Bloomgren","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107147_bib0005","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1212\/NXI.0000000000000195","article-title":"Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values","volume":"3","author":"Schwab","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107147_bib0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jcv.2013.02.002","article-title":"A second-generation ELISA (STRATIFY JCV\u2122 DxSelect\u2122) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification","volume":"57","author":"Lee","year":"2013","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.msard.2026.107147_bib0007","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1474-4422(17)30282-X","article-title":"Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies","volume":"16","author":"Ho","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2026.107147_bib0008","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/14712598.2023.2290530","article-title":"Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial","volume":"23","author":"Wessels","year":"2023","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.msard.2026.107147_bib0009","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1001\/jamaneurol.2022.5007","article-title":"Efficacy and safety of proposed biosimilar Natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the Antelope phase 3 randomized clinical trial","volume":"80","author":"Hemmer","year":"2023","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2026.107147_bib0010","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/PSY.0b013e3182294a50","article-title":"The nocebo effect and its relevance for clinical practice","volume":"73","author":"Colloca","year":"2011","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.msard.2026.107147_bib0011","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/brain\/124.5.962","article-title":"The Multiple Sclerosis Impact scale (MSIS-29): a new patient-based outcome measure","volume":"124","author":"Hobart","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.msard.2026.107147_bib0012","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual. Life Outcomes."},{"key":"10.1016\/j.msard.2026.107147_bib0013","doi-asserted-by":"crossref","first-page":"e1579","DOI":"10.1212\/WNL.0000000000008357","article-title":"The natalizumab wearing-off effect: end of natalizumab cycle, recurrence of MS symptoms","volume":"93","author":"van Kempen","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2026.107147_bib0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody","volume":"411","author":"Rispens","year":"2011","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.msard.2026.107147_bib0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2025.0337","article-title":"Accuracy of new John Cunningham virus antibody assay in Natalizumab-treated patients with multiple sclerosis","author":"Gelissen","year":"2025","journal-title":"JAMa Neurol."},{"key":"10.1016\/j.msard.2026.107147_bib0016","article-title":"Real-world experience with switching from originator to biosimilar natalizumab","author":"H\u00f8gest\u00f8l","year":"2025","journal-title":"medRxiv."},{"key":"10.1016\/j.msard.2026.107147_bib0017","article-title":"MS patients suffer side-effects after NHS England switches to cheaper drug","author":"Campbell","year":"2025","journal-title":"Guardian"},{"key":"10.1016\/j.msard.2026.107147_bib0018","article-title":"MS patient\u2019s life \u2018crumbling\u2019 after being switched to cheaper drug under NHS cost-cutting drive","author":"Evans","year":"2025","journal-title":"Independent"},{"key":"10.1016\/j.msard.2026.107147_bib0019","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1177\/13524585251346652","article-title":"A comparison of JC virus assay performance provided with originator and biosimilar natalizumab","volume":"31","author":"Varley","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107147_bib0020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1177\/13524585251322683","article-title":"Beyond the switch to the biosimilar of natalizumab: what is the impact of changing the JCV test?","volume":"31","author":"Vukusic","year":"2025","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107147_bib0021","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/acn3.51130","article-title":"Improving risk-stratification of natalizumab-associated PML","volume":"8","author":"Tugemann","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2026.107147_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104251","article-title":"Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis","volume":"68","author":"Gaughan","year":"2022","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001835?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001835?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:25:20Z","timestamp":1781526320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":22,"alternative-id":["S2211034826001835"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107147","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and patient experiences with the natalizumab biosimilar in multiple sclerosis treatment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107147"}}